Empagliflozin Improves Outcomes in Patients with Heart Failure and Preserved Ejection Fraction Irrespective of Age (JACC July 2022-1)

Description

The purpose of this study was to evaluate the interplay of age and empagliflozin effects in EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction).

Editors

Editor-in-Chief
Valentin Fuster, MD, PhD, MACC

CME Editor
Ragavendra R. Baliga, MD

Authors
Michael Böhm, MD

Nicholas D. Gollop, MB BCH, PhD

Martina Brueckmann, MD

Important Dates

Date of Release: June 27, 2022
Term of Approval/Date of CME/MOC/ECME Expiration: June 26, 2023

Summary


Availability:	On-Demand
	Expires on Jun 26, 2023


Cost:	FREE

Credit Offered:

1 CME Credit

1 ABIM-MOC Point